Marshall Wace’s Aquestive Therapeutics AQST Stock Holding History

Marshall Wace’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Buy	285,659 +267,344	+1,460%	+$1.13M	﹤0.01%	2110
2026 Q1	$76K	Buy	+18,315	New	+$74.3K	﹤0.01%	2930
2025 Q4	–	Sell	-371,066	Closed	-$2.07M	–	2932
2025 Q3	$2.07M	Buy	371,066 +298,487	+411%	+$1.29M	﹤0.01%	1596
2025 Q2	$240K	Buy	+72,579	New	+$208K	﹤0.01%	2402
2025 Q1	–	Sell	-55,695	Closed	-$198K	–	2611
2024 Q4	$198K	Buy	+55,695	New	+$257K	﹤0.01%	2354
2024 Q3	–	Sell	-77,016	Closed	-$200K	–	2475
2024 Q2	$200K	Buy	+77,016	New	+$257K	﹤0.01%	2298
2024 Q1	–	Sell	-288,884	Closed	-$584K	–	2414
2023 Q4	$584K	Sell	288,884 -21,925	-7%	-$38.7K	﹤0.01%	1656
2023 Q3	$476K	Buy	310,809 +38,414	+14%	+$66.1K	﹤0.01%	1742
2023 Q2	$449K	Buy	+272,395	New	+$493K	﹤0.01%	2022

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace's AQST Position: Q2 2026 in Review

Marshall Wace increased its Aquestive Therapeutics (AQST) stake by 1,460% in Q2 2026, buying an estimated $1.13M and bringing the position to 285,659 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Marshall Wace first reported a position in AQST in Q2 2023 and has held it in 9 quarters since. The position peaked at $2.07M in Q3 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Marshall Wace held 285,659 shares of Aquestive Therapeutics worth $1.19M as of Q2 2026.
Marshall Wace bought 267,344 Aquestive Therapeutics shares in Q2 2026, an estimated $1.13M.
Aquestive Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2110 holding.
Marshall Wace first reported a position in Aquestive Therapeutics in Q2 2023 and has held it in 9 quarters since.
Marshall Wace's Aquestive Therapeutics position peaked at $2.07M in Q3 2025.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.